small molecules

Novo inks $2.2B deal for Septerna's preclinical obesity programs

Novo offered more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Nick Paul Taylor May 14, 2025 7:00am

pivot change turnaround direction walk away

Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial

Apr 24, 2025 4:46am

Royal crown for princess and queen on dark red background

Empress' crown slips as biotech lays off over half of workers

Mar 18, 2025 1:20pm

Newleos unveils with $93M and 4 ex-Roche programs

Feb 13, 2025 12:00am

Kronos lays off 83% of staff, changes CEO after clinical setback

Nov 27, 2024 9:56am

heart cardio cardiovascular heart health

Lilly's lipoprotein-blocking heart drug posts midstage trial win

Nov 19, 2024 9:55am